Moderna to use Roche tests in COVID-19 vaccine trials

By The Science Advisory Board staff writers

December 9, 2020 -- Moderna will use Roche's Elecsys anti-SARS-CoV-2 S antibody test in its messenger RNA (mRNA)-1273 vaccine research trials. The test can quantitatively measure the level of antibodies against SARS-CoV-2 in vaccine trial participants.

The companies believe that the test could help to establish a correlation between vaccinations and protection from COVID-19. Moderna's vaccine triggers an antibody response specifically to the anti-receptor binding domain of the SARS-CoV-2 spike protein. Ultimately, the correlation could help Moderna assess if, or when, revaccination would be necessary.

Canada increases order for Moderna's COVID-19 vaccine
The Canadian government has increased its confirmed order of Moderna's COVID-19 vaccine candidate, messenger RNA (mRNA)-1273, by 20 million doses,...
Moderna's COVID-19 vaccine demonstrates durable immunity in early clinical trial
Moderna published interim data from a National Institutes of Health-led phase I study of its messenger RNA (mRNA)-1273 COVID-19 vaccine on December 3...
FDA sets advisory meeting date to discuss Moderna COVID-19 vaccine
The U.S. Food and Drug Administration (FDA) has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee for December 17...
Moderna to file COVID-19 vaccine EUA request
Moderna said it plans to request on November 30 an emergency use authorization (EUA) from the U.S. Food and Drug Administration and conditional marketing...
EMA recommends approval of Roche's mAb breast cancer product
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use has recommended the approval of Roche's Phesgo, a fixed-dose combination...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter